RET
46 programs · 45 companies
Programs
46
Companies
45
Active Trials
30
Targeting RET
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | EoEProstate Ca | |
| Fixanesiran | AbbVie | Preclinical | Endometrial CaHS | |
| BMY-8678 | Bristol-Myers Squibb | Approved | AS | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | CholangiocarcinomaPSP | |
| ARG-3458 | Argenx | Preclinical | DravetCKD | |
| Nidaratamab | Krystal Biotech | Preclinical | Hemophilia A | |
| Fixabrutinib | Verve | Phase 1 | T2D | |
| Nidarelsin | Uniqure | Phase 2/3 | Ewing SarcomaThymoma | |
| SOB-2861 | Sobi | Phase 2 | CKD | |
| Polasertib | Sobi | Phase 1 | NSCLCRB | |
| 450-8514 | Astellas | Phase 3 | PsANB | |
| Datozasiran | Cipla | NDA/BLA | FLSchizophrenia | |
| Capitapinarof | Otsuka | Preclinical | Endometrial CaSchizophrenia | |
| NCI-IIT-252 | NCI | Approved | FTD | |
| STA-IIT-824 | Stanford Medicine | Phase 1/2 | Thymoma | |
| SEP-123 | Septerna | Phase 1/2 | SMAMDS | |
| PRQ-8250 | ProQR Therapeutics | Phase 2/3 | CKDLN | |
| CLR-3690 | Cellectar Bio | Phase 3 | Alzheimer'sPompe | |
| Sovabrutinib | Evofem Bio | NDA/BLA | CSU | |
| Gelizasiran | NorthStar Medical | Phase 3 | SMABladder Ca | |
| MOM-9396 | Momenta (J&J) | Phase 1 | Huntington's | |
| 117-5200 | Sino Biopharma | Phase 2 | SMA | |
| Capitinib | Alteogen | Phase 1 | CKDCSU | |
| Elranesiran | MiNT Ther | Phase 1 | NSCLC | |
| KAR-5490 | Kartos | Phase 1 | EpilepsyRSV | |
| Olpacilimab | Remix Ther | Phase 1 | Urothelial CaSLE | |
| RGN-9803 | REGENXBIO | NDA/BLA | SLESCD | |
| ALD-7113 | Aldel Bio | Phase 3 | Pompe | |
| TUR-6841 | Turnstone Bio | Phase 1 | OCDAsthma | |
| 199-761 | ToolGen | Phase 2 | ETMG | |
| NAT-2164 | Natco Pharma | Phase 1/2 | Gastric CaCTCL | |
| Rimavorutinib | Windlas Bio | Phase 1 | OCD | |
| GLO-9650 | Gloria Bio | Phase 2 | DLBCLRCC | |
| SRR-6281 | Scholar Rock | Phase 1/2 | ALLRett | |
| Datomavacamten | Indivior | Phase 2/3 | Schizophrenia | |
| Polacagene | Redx Pharma | Approved | UC | |
| Ivozumab | Obseva (XOMA) | Phase 1 | HCCRA | |
| Ivofutibatinib | Mithra Pharma | Phase 3 | Cervical Ca | |
| Talaosocimab | MiNA Therapeutics | Phase 1 | FSGSMCL | |
| Nidanesiran | Liomont | Preclinical | HNSCCTTR Amyloidosis | |
| ROY-IIT-520 | Royal Marsden | Phase 2/3 | Wilms | |
| Tezevorutinib | Grand Pharma | Phase 1/2 | DravetMDS | |
| Niraratamab | GH Research | Phase 2/3 | AsthmaMDD | |
| RGE-5524 | Repligen | Phase 1 | Atopic DermMelanoma | |
| Surabrutinib | Grünenthal | Phase 2 | HCCDLBCL | |
| VCY-7977 | Veracyte | Phase 3 | Ewing SarcomaMG |